Short name: CMC 001, central moiety: Mn2+
CMC 001 is an orally administered
MRI contrast agent in development for enhancement of the
liver, bile ducts and gastrointestinal tract. Applications are screening of
liver tumors/metastases, imaging of the biliary tract and it could be suitable for
liver function studies by following the metabolism and excretion of manganese in the
liver cells.
Several advantages like better images, higher
safety, lower costs and less inconvenience for the patient can be expected.
Animal experiments and clinical studies in humans
Phase I and
Phase II A, have shown excellent
contrast enhancing properties with only minimal adverse effects.
CMC 001 is under development by the Medicon Valley based
CMC Contrast AB to receive a cost effective, safe and highly diagnostic MR
contrast medium for
abdominal MR imaging. Clinical studies
in Phase III are started.